Abstract
Thyrotoxicosis can lead to thyrotoxic periodic paralysis (TPP), an endocrine channelopathy, and is the most common cause of acquired periodic paralysis. Typically, paralytic attacks cease when hyperthyroidism is abolished, and recur if hyperthyroidism returns. TPP is often underdiagnosed, as it has diverse periodicity, duration and intensity. The age at which patients develop TPP closely follows the age at which thyrotoxicosis occurs. All ethnicities can be affected, but TPP is most prevalent in people of Asian and, secondly, Latin American descent. TPP is characterized by hypokalemia, suppressed TSH levels and increased levels of thyroid hormones. Nonselective β adrenergic blockers, such as propranolol, are an efficient adjuvant to antithyroid drugs to prevent paralysis; however, an early and definitive treatment should always be pursued. Evidence indicates that TPP results from the combination of genetic susceptibility, thyrotoxicosis and environmental factors (such as a high-carbohydrate diet). We believe that excess T3 modifies the insulin sensitivity of skeletal muscle and pancreatic β cells and thus alters potassium homeostasis, but only leads to a depolarization-induced acute loss of muscle excitability in patients with inherited ion channel mutations. An integrated etiopathophysiological model is proposed based on molecular findings and knowledge gained from long-term follow-up of patients with TPP.
Key Points
-
Thyrotoxic periodic paralysis (TPP) is characterized by attacks of acute muscle weakness, hypokalemia and thyrotoxic symptoms; it results from the combination of genetic susceptibility, thyrotoxicosis and environmental factors
-
People of Asian descent are most often affected, but all ethnicities can present with TPP
-
Hypokalemia is typical during paralysis, but is not always detected; administration of potassium during the attacks should be offered cautiously, preferably orally, to prevent rebound hyperkalemia
-
Most patients are first diagnosed with paralysis and later with thyrotoxicosis; delay in the diagnosis is frequent and, therefore, all cases of acute weakness in young males should raise suspicion
-
Early and definitive treatment of thyrotoxicosis is necessary to prevent new attacks of muscle weakness
-
Mutations in Kir2.6, a potassium ion channel, which occur in up to 33% of patients, reinforces the hypothesis of genetic heterogeneity in patients with TPP
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Silva, M. R., Chiamolera, M. I., Kasamatsu, T. S., Cerutti, J. M. & Maciel, R. M. Thyrotoxic hypokalemic periodic paralysis, an endocrine emergency: clinical and genetic features in 25 patients [Portuguese]. Arq. Bras. Endocrinol. Metabol. 48, 196–215 (2004).
Lin, S. H. Thyrotoxic periodic paralysis. Mayo Clin. Proc. 80, 99–105 (2005).
Dias da Silva, M. R. et al. Mutations linked to familial hypokalaemic periodic paralysis in the calcium channel alpha1 subunit gene (Cav1.1) are not associated with thyrotoxic hypokalaemic periodic paralysis. Clin. Endocrinol. (Oxf.) 56, 367–375 (2002).
Hackshaw, K. V. & Coker, E. Hypokalemic periodic paralysis in a hyperthyroid black woman. J. Natl Med. Assoc. 80, 1343–1344 (1988).
Kelley, D. E., Gharib, H., Kennedy, F. P., Duda, R. J. Jr & McManis, P. G. Thyrotoxic periodic paralysis. Report of 10 cases and review of electromyographic findings. Arch. Intern. Med. 149, 2597–2600 (1989).
Hay, I. D. & McDougall, I. R. Letter: Thyrotoxic periodic paralysis in Britain. Br. Med. J. 4, 761 (1975).
Engel, A. G. Thyroid function and periodic paralysis. Am. J. Med. 30, 327–333 (1961).
Rosenfeld, M. Acute aufsteigende lahmung bei morbus Basedow [German]. Klin. Wochenschr. (Berl.) 39, 538–540 (1902).
Dunlap, H. F. & Kepler, E. J. A syndrome resembling familial periodic paralysis occurring in the course of exolphthalmic goiter. Endocrinology 15, 541–546 (1931).
Pereira, V. G., Wajchenberg, B. L. & Quintão, E. R. Periodic paralysis associated with hyperthyroidism. Study of the precipitating factors. Arq. Bras. Endocrinol. Metabol. 17, 55–67 (1968).
Sterian, L. & Maciel, R. M. B. Paralisia periódica tirotóxica, relato de um caso e comentários etiopatogênicos [Portuguese]. Arq. Bras. Endocrinol. Metabol. 27, 161–162 (1983).
Ober, K. P. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine (Baltimore) 71, 109–120 (1992).
Manoukian, M. A., Foote, J. A. & Crapo, L. M. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch. Intern. Med. 159, 601–606 (1999).
Dias da Silva, M. R., Cerutti, J. M., Arnaldi, L. A. & Maciel, R. M. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J. Clin. Endocrinol. Metab. 87, 4881–4884 (2002).
Ryan, D. P. et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 140, 88–98 (2010).
Chen, L. et al. Clinical and molecular analysis of Chinese patients with thyrotoxic periodic paralysis. Eur. Neurol. 49, 227–230 (2003).
Ko, G. T. et al. Thyrotoxic periodic paralysis in a Chinese population. QJM 89, 463–468 (1996).
Zhang, M. Y. Clinical analysis of 50 cases of thyrotoxic periodic paralysis [Chinese]. Zhonghua Shen Jing Jing Shen Ke Za Zhi 20, 33–36 (1987).
Tamai, H. et al. HLA and thyrotoxic periodic paralysis in Japanese patients. J. Clin. Endocrinol. Metab. 64, 1075–1078 (1987).
Okihiro, M. M. & Beddow, R. M. Thyrotoxic periodic paralysis in Hawaii. Its predilection for the Japanese race. Neurology 15, 253–255 (1965).
Shiang, J. C. et al. Therapeutic analysis in Chinese patients with thyrotoxic periodic paralysis over 6 years. Eur. J. Endocrinol. 161, 911–916 (2009).
Maciel, R. M. B. Screening for thyrotoxic paralysis out of Asia: are we underestimating its frequency in the West? Presented at the 12th International Thyroid Congress, Kyoto, Japan. Endocr. J. 47 (Suppl. 2) WS-3 (2000).
Magsino, C. H. Jr & Ryan, A. J. Jr. Thyrotoxic periodic paralysis. South. Med. J. 93, 996–1003 (2000).
Bernard, J. D., Larson, M. A. & Norris, F. H. Jr. Thyrotoxic periodic paralysis in Californians of Mexican and Filipino ancestry. Calif. Med. 116, 70–74 (1972).
Castro Vilanova, M. D., Berbel, A., Posada, I. J. & Bermejo, F. Periodic thyrotoxic paralysis in Hispanics [Spanish]. Neurologia 12, 428–429 (1997).
Cesur, M. et al. Thyrotoxic hypokalaemic periodic paralysis in a Turkish population: three new case reports and analysis of the case series. Clin. Endocrinol. (Oxf.) 68, 143–152 (2008).
Chatterjee, A. K., Dhakam, Z., Morrish, N. J. & Manford, M. R. Thyrotoxic periodic paralysis in a Caucasian male. Hosp. Med. 65, 182–183 (2004).
Elston, M. S., Orr-Walker, B. J., Dissanayake, A. M. & Conaglen, J. V. Thyrotoxic, hypokalaemic periodic paralysis: Polynesians, an ethnic group at risk. Intern. Med. J. 37, 303–307 (2007).
Gordon, D. L., Agrawal, L., Swade, T. F. & Lawrence, A. M. Thyrotoxic hypokalemic periodic paralysis: six cases in non-Asian patients. Endocr. Pract. 4, 142–145 (1998).
Kilpatrick, R. E., Seiler-Smith, S. & Levine, S. N. Thyrotoxic hypokalemic periodic paralysis: report of four cases in black American males. Thyroid 4, 441–445 (1994).
Pichon, B. et al. Thyrotoxic periodic paralysis in Caucasian patients: a diagnostic challenge. Eur. J. Intern. Med. 16, 372–374 (2005).
Piraino Neuenschwander, P., Pumarino Carte, H., Bidegain González, F., Zura Jiménez, M. L. & Ferreiro Merino, F. Thyrotoxic hypokalemic periodic paralysis: 18 cases with different forms of thyrotoxicosis [Spanish]. Rev. Clin. Esp. 195, 294–297 (1995).
Reisin, R. C. et al. Thyrotoxic periodic paralysis in caucasians. Report of 8 cases. Neurologia 15, 222–225 (2000).
Sinharay, R. Hypokalaemic thyrotoxic periodic paralysis in the UK. QJM 96, 611–613 (2003).
Wild, E. Thyrotoxic periodic paralysis in a Maori patient. N. Z. Med. J. 117, U1204 (2004).
Williams, R. Thyrotoxic periodic paralysis in Navajos--HLA typing. West. J. Med. 142, 260–261 (1985).
Tran, H. A. et al. Thyrotoxic, hypokalaemic periodic paralysis in Australasian men. Intern. Med. J. 33, 91–94 (2003).
McFadzean, A. J. & Yeung, R. Familial occurrence of thyrotoxic periodic paralysis. Br. Med. J. 1, 760 (1969).
Shizume, K. et al. Comparison of the incidence of association of periodic paralysis and hyperthyroidism in Japan in 1957 and 1991. Endocrinol. Jpn. 39, 315–318 (1992).
McKenzie, T. Hypokalemic periodic paralysis of thyrotoxic origin: a case complicated by cultural differences. Can. Med. Assoc. J. 128, 950–951 (1983).
Nellen, H. et al. Thyrotoxic periodic paralysis in Mexican mestizo patients: a clinical, biochemical and HLA-serological study. Arch. Med. Res. 30, 74–76 (1999).
Iheonunekwu, N. C., Ibrahim, T. M., Davies, D. & Pickering, K. Thyrotoxic hypokalaemic paralysis in a pregnant Afro-Caribbean woman. A case report and review of the literature. West Indian Med. J. 53, 47–49 (2004).
Donovan, L., Parkins, V. M. & Mahalingham, A. Thyrotoxic periodic paralysis in pregnancy with impaired glucose tolerance: a case report and discussion of management issues. Thyroid 17, 579–583 (2007).
Richey, S. D. & Wendel, G. D. Jr. Thyrotoxic hypokalemic periodic paralysis following second-trimester prostaglandin-induced abortion. Obstet. Gynecol. 82 (Suppl.), 696–698 (1993).
Ptácek, L. J. Channel surfing. J. Clin. Endocrinol. Metab. 87, 4879–4880 (2002).
Leung, A. K. Familial 'hashitoxic' periodic paralysis. J. R. Soc. Med. 78, 638–640 (1985).
Hsieh, M. J. et al. Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks. Eur. J. Neurol. 15, 559–564 (2008).
Wong, G. W., Leung, T. F., Lo, A. F., Ahuja, A. T. & Cheng, P. S. Thyrotoxic periodic paralysis in a 14-year-old boy. Eur. J. Pediatr. 159, 934 (2000).
Tagami, T., Usui, T., Shimatsu, A. & Naruse, M. Toxic thyroid adenoma presenting as hypokalemic periodic paralysis. Endocr. J. 54, 797–803 (2007).
Ober, K. P. & Hennessy, J. F. Jodbasedow and thyrotoxic periodic paralysis. Arch. Intern. Med. 141, 1225–1227 (1981).
Laroia, S. T., Zaw, K. M., Ganti, A. K., Newman, W. & Akinwande, A. O. Amiodarone-induced thyrotoxicosis presenting as hypokalemic periodic paralysis. South. Med. J. 95, 1326–1328 (2002).
Kiso, Y. et al. A case of thyrotropin (TSH)-secreting tumor complicated by periodic paralysis. Jpn. J. Med. 29, 399–404 (1990).
Hsu, F. S. et al. Thyrotropin-secreting pituitary adenoma presenting as hypokalemic periodic paralysis. Am. J. Med. Sci. 325, 48–50 (2003).
Chen, Y. C., Fang, J. T., Chang, C. T. & Chou, H. H. Thyrotoxic periodic paralysis in a patient abusing thyroxine for weight reduction. Ren. Fail. 23, 139–142 (2001).
Chou, H. K., Tsao, Y. T. & Lin, S. H. An unusual cause of thyrotoxic periodic paralysis: triiodothyronine-containing weight reducing agents. Am. J. Med. Sci. 337, 71–73 (2009).
Hannon, M. J., Behan, L. A. & Agha, A. Thyrotoxic periodic paralysis due to excessive L-thyroxine replacement in a Caucasian man. Ann. Clin. Biochem. 46, 423–425 (2009).
Lin, S. H., Davids, M. R. & Halperin, M. L. Hypokalaemia and paralysis. QJM 96, 161–169 (2003).
Fisher, J. Thyrotoxic periodic paralysis with ventricular fibrillation. Arch. Intern. Med. 142, 1362–1364 (1982).
Loh, K. C., Pinheiro, L. & Ng, K. S. Thyrotoxic periodic paralysis complicated by near-fatal ventricular arrhythmias. Singapore Med. J. 46, 88–89 (2005).
Miyashita, Y. et al. Ventricular fibrillation due to severe hypokalemia induced by steroid treatment in a patient with thyrotoxic periodic paralysis. Intern. Med. 45, 11–13 (2006).
Wu, C. Z., Wu, Y. K., Lin, J. D. & Kuo, S. W. Thyrotoxic periodic paralysis complicated by acute hypercapnic respiratory failure and ventricular tachycardia. Thyroid 18, 1321–1324 (2008).
Kokenge, F. & Heiner, M. Thyrotoxic periodic paralysis: a peculiar case with weekend-related quadriplegia. Endocrinologist 15, 297–299 (2005).
Liu, Z., Braverman, L. E. & Malabanan, A. Thyrotoxic periodic paralysis in a Hispanic man after the administration of prednisone. Endocr. Pract. 12, 427–431 (2006).
Kane, M. P. & Busch, R. S. Drug-induced thyrotoxic periodic paralysis. Ann. Pharmacother. 40, 778–781 (2006).
Wongraoprasert, S., Buranasupkajorn, P., Sridama, V. & Snabboon, T. Thyrotoxic periodic paralysis induced by pulse methylprednisolone. Intern. Med. 46, 1431–1433 (2007).
Kemperman, F. A., Hoff, H. C. & de Klerk, G. Hypokalemic periodic paralysis as the sole manifestation of hyperthyroidism [Dutch]. Ned. Tijdschr. Geneeskd. 139, 938–941 (1995).
Shizume, K. et al. Studies on electrolyte metabolism in idiopathic and thyrotoxic periodic paralysis. I. Arteriovenous differences of electrolytes during induced paralysis. Metabolism 15, 138–144 (1966).
Feely, J. Potassium shift in thyrotoxic periodic paralysis. Postgrad Med. J. 57, 238–239 (1981).
Chan, A., Shinde, R., Chow, C. C., Cockram, C. S. & Swaminathan, R. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ 303, 1096–1099 (1991).
Gaul, C., Leonhardt, G., Spens, A., Schneyer, U. & Zierz, S. Hypokalemic thyrotoxic periodic paralysis (HTPP). Rare differential diagnosis in case of acute tetraparesis in Europe [German]. Med. Klin. (Munich) 100, 583–586 (2005).
Neal, J. M. Thyrotoxic periodic paralysis in a Caucasian man: recognition and diagnosis. Indiana Med. 84, 696–699 (1991).
Lin, S. H. & Lin, Y. F. Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis. Am. J. Kidney Dis. 37, 620–623 (2001).
Norris, K. C., Levine, B. & Ganesan, K. Thyrotoxic periodic paralysis associated with hypokalemia and hypophosphatemia. Am. J. Kidney Dis. 28, 270–273 (1996).
Lin, S. H. et al. Early diagnosis of thyrotoxic periodic paralysis: spot urine calcium to phosphate ratio. Crit. Care Med. 34, 2984–2989 (2006).
Bernard, P., Rault, A. & Talarmin, F. Hypokalemic periodic paralysis at initiation of Graves' disease treatment. Two observations [French]. Presse Med. 30, 221 (2001).
Navarro, V., Fournier, E., Girard, S., Delattre, J. Y. & Eymard, B. Periodic hypokalemic paralysis as the manifestation of Graves' disease: clinical and electrophysiological study [French]. Rev. Neurol. (Paris) 156, 59–61 (2000).
Hawkins, B. R., Ma, J. T., Lam, K. S., Wang, C. C. & Yeung, R. T. Association of HLA antigens with thyrotoxic Graves' disease and periodic paralysis in Hong Kong Chinese. Clin. Endocrinol. (Oxf.) 23, 245–252 (1985).
Puvanendran, K., Cheah, J. S. & Wong, P. K. Electromyographic (EMG) study in thyrotoxic periodic paralysis. Aust. N. Z. J. Med. 7, 507–510 (1977).
Tengan, C. H. et al. Periodic paralysis: anatomo-pathological study of skeletal muscles in 14 patients [Portuguese]. Arq. Neuropsiquiatr. 52, 32–40 (1994).
Cheah, J. S., Tock, E. P. & Kan, S. P. The light and electron microscopic changes in the skeletal muscles during paralysis in thyrotoxic periodic paralysis. Am. J. Med. Sci. 269, 365–374 (1975).
Sokolina, N. A., Il'ina, N. A. & Korolev, V. V. Change in the ultrastructure of the muscles in thyrotoxic periodic paralysis [Russian]. Arkh. Patol. 38, 27–33 (1976).
Tassone, H., Moulin, A. & Henderson, S. O. The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature. J. Emerg. Med. 26, 157–161 (2004).
Shayne, P. & Hart, A. Thyrotoxic periodic paralysis terminated with intravenous propranolol. Ann. Emerg. Med. 24, 736–740 (1994).
Huang, T. Y. & Lin, S. H. Thyrotoxic hypokalemic periodic paralysis reversed by propranolol without rebound hyperkalemia. Ann. Emerg. Med. 37, 415–416 (2001).
Birkhahn, R. H., Gaeta, T. J. & Melniker, L. Thyrotoxic periodic paralysis and intravenous propranolol in the emergency setting. J. Emerg. Med. 18, 199–202 (2000).
Yeung, R. T. & Tse, T. F. Thyrotoxic periodic paralysis. Effect of propranolol. Am. J. Med. 57, 584–590 (1974).
Caciotti, A., Morrone, A., Domenici, R., Donati, M. A. & Zammarchi, E. Severe prognosis in a large family with hypokalemic periodic paralysis. Muscle Nerve 27, 165–169 (2003).
Okihiro, M. M. & Nordyke, R. A. Hypokalemic periodic paralysis. Experimental precipitation with sodium liothyronine. JAMA 198, 949–951 (1966).
Gallagher, E. J. Is thyrotoxic periodic paralysis a “channelopathy”? J. Emerg. Med. 17, 123–127 (1999).
Chan, A., Shinde, R., Chow, C. C., Cockram, C. S. & Swaminathan, R. Hyperinsulinaemia and Na+, K(+)-ATPase activity in thyrotoxic periodic paralysis. Clin. Endocrinol. (Oxf.) 41, 213–216 (1994).
Shishiba, Y., Shimizu, T., Saito, T. & Shizume, K. Elevated immunoreactive insulin concentration during spontaneous attacks in thyrotoxic periodic paralysis. Metabolism 21, 285–290 (1972).
Soonthornpun, S., Setasuban, W. & Thamprasit, A. Insulin resistance in subjects with a history of thyrotoxic periodic paralysis (TPP). Clin. Endocrinol. (Oxf.) 70, 794–797 (2009).
Hamada, N. et al. Transient glucose intolerance during attacks of thyrotoxic periodic paralysis. Horm. Metab. Res. 17, 301–305 (1985).
Holloszy, J. O. & Hansen, P. A. Regulation of glucose transport into skeletal muscle. Rev. Physiol. Biochem. Pharmacol. 128, 99–193 (1996).
Clausen, T. Hormonal and pharmacological modification of plasma potassium homeostasis. Fundam. Clin. Pharmacol. 24, 595–605 (2010).
Antes, L. M., Kujubu, D. A. & Fernandez, P. C. Hypokalemia and the pathology of ion transport molecules. Semin. Nephrol. 18, 31–45 (1998).
Abbott, G. W. et al. MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis. Cell 104, 217–231 (2001).
Tricarico, D., Servidei, S., Tonali, P., Jurkat-Rott, K. & Camerino, D. C. Impairment of skeletal muscle adenosine triphosphate-sensitive K+ channels in patients with hypokalemic periodic paralysis. J. Clin. Invest. 103, 675–682 (1999).
Cannon, S. C. An expanding view for the molecular basis of familial periodic paralysis. Neuromuscul. Disord. 12, 533–543 (2002).
Ruff, R. L. Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current. Neurology 53, 1556–1563 (1999).
Puwanant, A. & Ruff, R. L. INa and IKir are reduced in Type 1 hypokalemic and thyrotoxic periodic paralysis. Muscle Nerve 42, 315–327 (2010).
Lin, H. et al. Thyroid hormones suppress ɛ-PKC signalling, down-regulate connexin-43 and increase lethal arrhythmia susceptibility in non-diabetic and diabetic rat hearts. J. Physiol. Pharmacol. 59, 271–285 (2008).
Muscella, A. et al. PKC-ɛ-dependent cytosol-to-membrane translocation of pendrin in rat thyroid PC Cl3 cells. J. Cell Physiol. 217, 103–112 (2008).
Watanabe, H. et al. Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. Biochem. Biophys. Res. Commun. 308, 439–444 (2003).
Casas, F. et al. Overexpression of the mitochondrial T3 receptor p43 induces a shift in skeletal muscle fiber types. PLoS ONE 3, e2501 (2008).
Miyabara, E. H. et al. Thyroid hormone receptor-β-selective agonist GC-24 spares skeletal muscle type I to II fiber shift. Cell Tissue Res. 321, 233–241 (2005).
Biering, H., Bauditz, J., Pirlich, M., Lochs, H. & Gerl, H. Manifestation of thyrotoxic periodic paralysis in two patients with adrenal adenomas and hyperandrogenaemia. Horm. Res. 59, 301–304 (2003).
Azzarolo, A. M. et al. Androgen support of lacrimal gland function. Endocrine 6, 39–45 (1997).
Song, M. et al. Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones. J. Biol. Chem. 276, 31883–31890 (2001).
Ryan, D. P. & Ptácek, L. J. in The Molecular and Genetic Basis of Neurologic and Psychiatric Disease (eds Rosenberg, R. N., DiMauro, S., Paulson, H. L., Ptácek, L. J. & Nestler, E. J.) 550–568 (Lippincott Williams & Wilkins, Philadelphia, 2007).
Ng, W. Y., Lui, K. F., Thai, A. C. & Cheah, J. S. Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis. Thyroid 14, 187–190 (2004).
Wang, W. et al. Mutation screening in Chinese hypokalemic periodic paralysis patients. Mol. Genet. Metab. 87, 359–363 (2006).
Sternberg, D., Tabti, N., Fournier, E., Hainque, B. & Fontaine, B. Lack of association of the potassium channel-associated peptide MiRP2–R83H variant with periodic paralysis. Neurology 61, 857–859 (2003).
Lehmann-Horn, F. Disease-causing mutations or functional polymorphisms? Acta Myol. 23, 85–89 (2004).
Tang, N. L. et al. The α1S subunit of the L-type calcium channel is not a predisposition gene for thyrotoxic periodic paralysis. Clin. Endocrinol. (Oxf.) 66, 229–234 (2007).
Plaster, N. M. et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 105, 511–519 (2001).
Logothetis, D. E., Petrou, V. I., Adney, S. K. & Mahajan, R. Channelopathies linked to plasma membrane phosphoinositides. Pflugers Arch. 460, 321–341 (2010).
Nehring, R. B. et al. Neuronal inwardly rectifying K(+) channels differentially couple to PDZ proteins of the PSD-95/SAP90 family. J. Neurosci. 20, 156–162 (2000).
Leonoudakis, D. et al. Protein trafficking and anchoring complexes revealed by proteomic analysis of inward rectifier potassium channel (Kir2.x)-associated proteins. J. Biol. Chem. 279, 22331–22346 (2004).
Rolim, A. L. R. et al. Ion channelopathies in endocrinology: recent genetic findings and pathophysiological insights. Arq. Bras. Endocrinol. Metabol. 54, 673–681 (2010).
Acknowledgements
The authors thank the team of the Laboratory of Molecular and Translational Endocrinology, especially Reinaldo Furlanetto, Luiza Matsumura, Jairo Hidal, João Roberto Martins, Teresa Kasamatsu, Maria Izabel Chiamolera, Janete Cerutti, Ana Luiza Rolim, Cléber Camacho and Beatriz Freitas and all the collaborators at the Division of Endocrinology, Department of Medicine, Escola Paulista de Medicina, Federal University of Sao Paulo. We also thank the colleagues who referred patients for our genetic study, Drs. Adelaide Albergária-Pereira, Gisah Carvalho, Maria Cristina Costa, Cássia Jurado, Cláudio Kater, Maria Conceição Mamone, Gláucia Mazeto, Gabriela Saraiva, Célia Tengan and Matthias Kugler. The authors' research is supported by São Paulo State Research Foundation (FAPESP), Brazilian Research Council (CNPq) and Fleury Group.
Author information
Authors and Affiliations
Contributions
All authors contributed equally to all aspects of this review.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Maciel, R., Lindsey, S. & Dias da Silva, M. Novel etiopathophysiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol 7, 657–667 (2011). https://doi.org/10.1038/nrendo.2011.58
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.58